It's not curing patients, but it's giving responses, it's shrinking tumor, and you know one day, this drug in combination maybe with another drug will have a cure, but years ago, we didn't even have this drug. So we when patients received chemotherapy and failed, they didn't have ...
I was diagnosed with Stage 4 Colon Cancer. Surgery was necessary but I refused all other treatment, much to the disgust of the highly paid oncolgist.
42 However, the total therapeutic impact in clinical application is still not optimum. Melanin, as a natural photosensitizer, may be used to accomplish multimodal imaging and tumor therapy by various surface alterations.43 Jiang44,45 demonstrated that nanoparticles made of simple red cell membrane or...
I started on the cytotoxic daily drug Xeloda first (in addition to monthly infusions of Zometa) which gave me six months of success, shrinking the amount of cancer evident on PET scans. In April 2013 when my tumor markers started rising I started on the hormonal combo of Aromasin and ...
diagnosed, the drug regimen that the patient receives is based primarily on the results of a biopsy that is used to identify the type oftumorshe has. The effectiveness of the initial treatment is assessed after two to three months by determining whether the tumors are shrinking or continuing ...
This controllable shrinking–swelling transition based on laser-exposure or non-exposure makes the introduced hydrogels highly promising for drug delivery applications. We further evaluated the switchable changes in drug release in response to 'on-off ' switches of NIR light in pH 7.4 and 5.0 at ...
tumor cell density was assumed to be 5.8 × 108per cm3, as determined experimentally for lung cancer26. The choice of the density parameter should not be crucial in our model, as it simply scales everything in an equal manner and a different choice would not have an impact on the ...
This controllable shrinking–swelling transition based on laser-exposure or non-exposure makes the introduced hydrogels highly promising for drug delivery applications. We further evaluated the switchable changes in drug release in response to ‘on-off’ switches of NIR light in pH 7.4 and 5.0 at ...
K+ ion is key regulator of cell volume and shrinking of cell volume is a characteristic phenotypic modulation of cells undergoing apoptosis. Loss of intracellular K+ via activation of various ion channels leads to apoptosis by decay of the membrane potential and the associated Ca2+ influx, ...